Wednesday, December 16, 2020 9:37:33 AM
What is that link supposed to show?
Recent DFTX News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 12:15:16 PM
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder • Business Wire • 05/12/2026 11:00:00 AM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 05/11/2026 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:17:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:12:25 PM
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights • Business Wire • 05/07/2026 08:01:00 PM
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/30/2026 08:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/27/2026 08:07:02 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/27/2026 08:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 08:22:38 PM
- Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day • Business Wire • 04/22/2026 08:15:00 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 04/20/2026 08:01:00 PM
- Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments • Business Wire • 04/18/2026 11:38:00 PM
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events • Business Wire • 04/09/2026 11:00:00 AM
- New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States • Business Wire • 03/31/2026 11:00:00 AM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/30/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/26/2026 10:43:44 PM
- Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 • Business Wire • 03/26/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:41:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/25/2026 09:40:41 PM
- Definium Therapeutics Announces New Employee Inducement Grants • Business Wire • 03/09/2026 08:01:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (Canada) • 03/09/2026 02:50:00 PM
- CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions • PR Newswire (US) • 03/09/2026 02:50:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (US) • 02/27/2026 04:44:00 PM
- Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments • PR Newswire (Canada) • 02/27/2026 04:44:00 PM

